Company news

Nicox SA news in 2026

Nicox SA's news releases, calls and decks from 2026, newest first.

View company

Nicox Reports First Half 2026 Financial Results

October 29, 2026

Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026

September 16, 2026

Nicox: Les données sur NCX 470 seront présentées lors du Congrès annuel 2026 de l’AAOpt

September 15, 2026

Nicox Announces NCX 470 NDA in China Accepted for Review

September 11, 2026

Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 470

September 10, 2026

Nicox Announces Extension of Cash Runway

September 2, 2026

Nicox annonce l’extension de son horizon de trésorerie

September 1, 2026

Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma

August 26, 2026

Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension

August 9, 2026

Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment

July 1, 2026

Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company

June 23, 2026

Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470

June 18, 2026

Reminder: Nicox June 2024 Warrants will expire June 19, 2026

June 8, 2026

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative

June 3, 2026

Nicox Provides Full Year 2025 Financial Results and Corporate Update

April 30, 2026

Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026

April 20, 2026

Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting

February 24, 2026

Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470

February 16, 2026

Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026

February 10, 2026

Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations

January 20, 2026

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

January 12, 2026

Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing

January 5, 2026

Decks in 2026